Oklahoma Bill Aims to Cap Private Insulin Costs at $35

The proposal follows a 2022 law that limited insulin prices for Medicare patients.

Mar. 31, 2026 at 12:18am

Got story updates? Submit your updates here. ›

An extreme macro X-ray photograph revealing the internal molecular structure of an insulin vial, with its ghostly, glowing lines and forms against a dark background, conceptually representing efforts to improve insulin affordability.A new Oklahoma bill seeks to limit the out-of-pocket cost of insulin for private insurance patients, building on recent federal efforts to improve access to this life-saving medication.Oklahoma City Today

The Oklahoma state legislature is considering a new bill that would cap the monthly cost of insulin for people with private health insurance at $35. This proposal builds on a 2022 federal law that limited insulin costs to $35 per month for Medicare beneficiaries.

Why it matters

Insulin is a life-saving medication for people with diabetes, but its skyrocketing prices have made it unaffordable for many patients. This new state-level bill aims to improve insulin affordability and access, especially for working families with private insurance.

The details

The proposed legislation would limit the monthly out-of-pocket cost of insulin to $35 for Oklahomans with private health plans. This builds on a 2022 federal law that capped insulin costs at $35 per month for Medicare recipients.

  • In 2022, the federal government passed a law limiting insulin costs to $35 per month for Medicare patients.
  • The new Oklahoma bill is currently under consideration by the state legislature.

The players

Oklahoma State Legislature

The governing body of the state of Oklahoma that is considering the new insulin cost cap legislation.

Got photos? Submit your photos here. ›

What’s next

If passed, the Oklahoma bill would need to be signed into law by the state's governor before taking effect.

The takeaway

This proposed legislation in Oklahoma aims to build on recent federal efforts to improve insulin affordability, demonstrating a growing bipartisan push to make this critical medication more accessible for people with diabetes.